Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...

"It’s crucial that patients and their families know about this new option," said Dr. William Russell, an oncology radiologist ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Novartis radioligand therapy, Pluvicto gets US FDA approval for earlier use before chemotherapy in PSMA-positive mCRPC: Basel Monday, March 31, 2025, 13:00 Hrs [IST] Novartis anno ...

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food and Drug Administration (FDA) has expanded approval for Pluvicto (lutetium Lu 177 vipivotide ...

The FDA has expanded the approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and can delay chemotherapy.